VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
Need to revisit or download past content?
ACCESS AVAILABLE RESOURCES
from recent hematology-oncology congresses right here
2022
American Society of Clinical Oncology (ASCO)
2022
European Hematology Association (EHA)
2022
Society of Hematologic Oncology (SOHO)
2021
American Society of Hematology (ASH)
German Lymphoma Alliance (GLA) Meeting
November 10-12, 2022
Berlin, Germany
American Society of Hematology (ASH) Annual Meeting
December 10-13, 2022
New Orleans, Louisiana, United States & online
International Symposium on Acute Leukemias (ISAL) XVIII Meeting
March 19-22, 2023
Munich, Germany & online
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2-6, 2023
Chicago, Illinois, United States & online
European Hematology Association (EHA) Annual Meeting
June 8-11, 2023
Frankfurt, Germany & online
European School of Haematology (ESH) Meeting
7th Translational Research Conference: Lymphoid Malignancies
October 20-22, 2023
Estoril, Portugal
AML Venetoclax KEE Video — Dr Sierra (Full Video)
Use: External
ALL-VNCAML-210045
AML Venetoclax KEE Video — Dr Moshe (Full Video)
Use: External
ALL-VNCAML-210068
Venetoclax MoA AML Video
Use: External
ALL-VEN-210009
Fight for AML Video — Coach Voice
Use: External and Internal
ALL-VNCLY-210043
RIGHT START DIALOGUE TOOL
An interactive PDF you can use with patients and caregivers. Designed to support meaningful conversations about AML and Venclyxto. This tool covers:
- What is an AML diagnosis?
- Treatment initiation with Venclyxto
- How to take Venclyxto prescribed
DOSING GUIDE—STARTING PATIENTS ON VENCLYXTO
A booklet that you can share with your patients to help them understand. This dosing guide includes:
- How to take Venclyxto
- Dose modifications
- Tumour lysis syndrome prevention
- Key safety and lifestyle considerations while on Venclyxto
AML THERAPY OPTIMIZATION TOOL KIT
A tool kit, for your use only, with key information to help you successfully initiate and manage your patients' AML treatment with Venclyxto. This kit includes:
- Considerations before starting Venclyxto
- How to start Venclyxto/the AML ramp-up dosing schedule
- Key safety information and dosing/schedule modifications
- Drug-drug interactions and Venclyxto dose modifications
I want to know how VENCLYXTO's MoA works
I want to review the adverse events profile
Reference: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG. 2021.
ALL-VNCAML-210081 February 2022